Madrigal Pharmaceuticals Inc
MDGLHealthcare|Biotechnology|USA
$536.70
-23.77 (-4.24%)
Tangible Book
$23.27
About
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
Stock Price
+70.6%(1Y)
Pipeline Summary
18 total trials10
Phase 1
3
Phase 2
4
Phase 3
0
Phase 4
Completed: 13Active: 3Recruiting: 2
Active Trials (5)
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
NCT05500222NASH
Phase 3Active
Enrollment: 845 participants
A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
NCT03900429NASH - Nonalcoholic Steatohepatitis
Phase 3Active
Enrollment: 1,759 participants
Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
NCT07335601MASH - Metabolic Dysfunction-Associated Steatohepatitis
Phase 2Recruiting
Enrollment: 120 participants
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
NCT04951219Non-Alcoholic Fatty Liver Disease
Phase 3Active
Enrollment: 810 participants
Rezdiffra Pregnancy and Lactation Registry
NCT07541469MASH - Metabolic Dysfunction-Associated Steatohepatitis
Recruiting
Enrollment: 10 participants
BioScore
7.3/10
Buy
Ownership
Recent Insider Trades
Soergel DavidSELL
2026-06-011,042 shares @ $495.74
Levy Richard SSELL
2026-05-225,682 shares @ $515.44
Soergel DavidSELL
2026-05-18844 shares @ $515.9
Huntsman CaroleSELL
2026-03-06419 shares @ $431.94
Dier MardiSELL
2026-03-061,982 shares @ $430.87
Data last updated: Jul 12, 2026, 07:31 PM